Patents by Inventor Christopher Lengauer

Christopher Lengauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P13K pathway mutations in cancer
    Patent number: 9580750
    Abstract: Given the important role of protein kinases in pathways affecting cellular growth and invasion, we have analyzed 340 serine/threonine kinases for genetic mutations in colorectal cancers. Mutations in eight genes were identified, including three members of the phosphatidylinositol-3-kinase (PI3K) pathway; the alterations in the latter genes each occurred in different tumors and did not overlap with mutations in PIK3CA or other non-serine-threonine kinase (STK) members of the PI3K pathway, suggesting that mutations in any of these genes had equivalent tumorigenic effects. These data demonstrate that the PI3K pathway is a major target for mutational activation in colorectal cancers and provide new opportunities for therapeutic intervention.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: February 28, 2017
    Assignee: The Johns Hopkins University
    Inventors: Donald William Parsons, Tian-li Wang, Yardena Samuels, Alberto Bardelli, Christopher Lengauer, Victor Velculescu, Kenneth W. Kinzler, Bert Vogelstein
  • P13k pathway mutations in cancer
    Publication number: 20110059434
    Abstract: Given the important role of protein kinases in pathways affecting cellular growth and invasion, we have analyzed 340 serine/threonine kinases for genetic mutations in colorectal cancers. Mutations in eight genes were identified, including three members of the phosphatidylinositol-3-kinase (PI3K) pathway; the alterations in the latter genes each occurred in different tumors and did not overlap with mutations in PIK3CA or other non-serine-threonine kinase (STK) members of the PI3K pathway, suggesting that mutations in any of these genes had equivalent tumorigenic effects. These data demonstrate that the PI3K pathway is a major target for mutational activation in colorectal cancers and provide new opportunities for therapeutic intervention.
    Type: Application
    Filed: May 23, 2006
    Publication date: March 10, 2011
    Inventors: Donald William Parsons, Tian-li Wang, Yardena Samuels, Alberto Bardelli, Christopher Lengauer, Victor Velculescu, Kenneth W. Kinzler, Bert Vogelstein